What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
KIT or PDGFRA mutation testing is molecular analysis of a gastrointestinal stromal tumor (GIST). It looks for the driver change that may make the tumor sensitive—or resistant—to a tyrosine-kinase inhibitor (TKI) such as imatinib. The result helps determine whether adjuvant treatment could reduce relapse risk after complete surgery, but it never replaces the pathology-based risk assessment.
For a resected GIST with a significant recurrence risk and an imatinib-sensitive KIT or PDGFRA alteration, the standard guideline approach is imatinib 400 mg once daily for three years. PDGFRA exon 18 D842V is a major exception: it predicts primary resistance, so adjuvant imatinib should not be used. KIT exon 9 may prompt a specialist discussion about a higher imatinib dose, while a mutation-negative (wild-type) result requires evaluation for other tumor biology before any adjuvant TKI decision.
As an Amazon Associate I earn from qualifying purchases.
What the test actually examines
The laboratory analyzes DNA from GIST tissue, usually material from a diagnostic biopsy or the resection specimen. The main targets are activating mutations in the KIT and PDGFRA genes. These genes encode receptor tyrosine kinases; when a driver mutation keeps the receptor abnormally active, the signal can promote tumor growth. TKIs work by inhibiting the abnormal KIT or PDGFRA signaling, as described in the National Cancer Institute’s GIST PDQ.
That makes the assay both a biological classification and a treatment-planning test. A pathology report can establish that a tumor is a GIST, but the mutation result gives the oncology team evidence about likely drug sensitivity. It is not a home test, a blood screening test for relatives, or a stand-alone prescription decision.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
SEOM-GEIS guidance describes KIT/PDGFRA molecular testing as mandatory when adjuvant treatment is indicated. British Sarcoma Group guidance uses the testing in a sequential algorithm: first establish whether a patient is an appropriate candidate for TKI treatment, then use the genotype to refine the choice and dose.
Why the mutation result cannot be interpreted by itself
Adjuvant therapy is treatment given after the surgeon has removed visible disease. The decision depends on the chance that microscopic disease will later cause a recurrence and on whether the tumor’s genotype is drug-sensitive. The mutation result answers the second question; it does not answer the first.
The recurrence-risk assessment incorporates:
- Primary tumor size.
- Anatomic site of the GIST.
- Mitotic rate, which reflects how quickly the cells are dividing.
- Tumor rupture, whether spontaneous or occurring during the clinical course.
- Surgical margins and whether the resection was complete.
Two tumors with the same mutation can therefore receive different recommendations if their size, site, mitotic activity, rupture status, or surgical findings differ. Conversely, a tumor categorized as high risk is not automatically treated with imatinib if its genotype predicts resistance.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →How each major result changes the adjuvant discussion
Imatinib-sensitive KIT or PDGFRA mutation
When the tumor has a mutation known to be sensitive to standard imatinib and the pathology shows a significant relapse risk, the ESMO-EURACAN-GENTURIS guideline (2021) identifies imatinib 400 mg per day for three years as the standard adjuvant treatment. The recommendation applies after complete resection; it is not a rule that every mutation-positive GIST needs medication.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
The oncology team still checks the full pathology report, the confidence that the tumor was completely removed, other medicines and medical conditions, and local prescribing rules. The mutation establishes a plausible treatment target, while the risk category establishes whether the expected benefit justifies three years of therapy.
KIT exon 11
KIT exon 11 is a common activating alteration and is generally considered imatinib-sensitive. In a patient whose resected tumor has significant recurrence risk, it supports the standard 400 mg daily, three-year adjuvant approach. The exon label is not a substitute for the mitotic rate, tumor site, size, rupture status, or margin assessment.
KIT exon 9
KIT exon 9 is associated with lower sensitivity to the standard imatinib dose. ESMO states that 800 mg daily for three years may be considered in the adjuvant setting. “May be considered” is important: a dose increase requires sarcoma-oncology supervision, assessment of tolerability and interactions, and confirmation that the higher dose is approved and practical in the relevant jurisdiction. Patients should not double their tablets without a written plan.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPDGFRA exon 18 D842V
PDGFRA exon 18 D842V predicts primary resistance to imatinib. ESMO states that a D842V-mutated GIST should not receive adjuvant therapy, and the National Cancer Institute notes that these tumors are unlikely to benefit from adjuvant imatinib. This remains true even when other pathology features suggest a high risk of recurrence; the expected drug sensitivity is the limiting factor.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
In advanced or unresectable disease, avapritinib is the genotype-directed option discussed in NCCN and ESMO guidance for D842V tumors. That does not make avapritinib an automatic substitute after surgery. Adjuvant treatment and treatment for persistent, unresectable, or metastatic disease are different clinical settings with different evidence and approvals.
No KIT or PDGFRA mutation: “wild-type” GIST
A report saying “wild-type” means that the tested KIT and PDGFRA changes were not identified; it does not mean the tumor has no molecular abnormality. The team should review for SDH-deficient GIST, NF1-associated disease, or other biology. These groups are generally unlikely to benefit from adjuvant imatinib, so a high-risk pathology category alone should not be used to infer that imatinib will work.
The next step may involve additional molecular or immunohistochemical characterization, depending on the pathology findings and local practice. The purpose is to identify the biology before exposing a patient to a long course of a TKI with little expected benefit.
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minuteMutation and treatment setting at a glance
| Result or situation | What it suggests | Adjuvant implication after complete resection | Important qualification |
|---|---|---|---|
| Imatinib-sensitive KIT or PDGFRA alteration with significant recurrence risk | Target is likely inhibited by imatinib | Imatinib 400 mg daily for three years is the ESMO standard | Risk assessment and surgical findings must support treatment |
| KIT exon 9 | Lower sensitivity to standard-dose imatinib | 800 mg daily for three years may be considered | Specialist supervision and local approval are required |
| PDGFRA exon 18 D842V | Primary imatinib resistance | Do not use adjuvant imatinib | Avapritinib is discussed for advanced disease, not as an automatic adjuvant replacement |
| No KIT or PDGFRA mutation (wild-type) | Another driver may be present | Adjuvant imatinib is generally unlikely to help | Evaluate SDH-deficient, NF1-associated, and other subtypes |
| Unresectable, recurrent, or metastatic GIST | Disease remains present or has returned | Managed under advanced-disease protocols rather than the three-year postoperative framework | Drug choice depends on genotype, prior treatment, and guideline approvals |
How testing fits into the care pathway
- Tissue is obtained. The laboratory uses a biopsy or resection specimen. The treating team should confirm that there is enough viable tumor for molecular analysis.
- Pathology establishes the diagnosis and risk features. The report records site, size, mitotic rate, rupture, margins, and other findings needed for recurrence-risk classification.
- Molecular testing identifies the driver. The assay reports a KIT or PDGFRA mutation when detected, including the exon and specific variant when relevant, or reports that no tested mutation was found.
- The result is matched to drug sensitivity. An imatinib-sensitive alteration, KIT exon 9, D842V, and a wild-type result lead to different discussions.
- The sarcoma team makes a shared decision. Doctors weigh expected benefit against treatment burden, comorbidities, interactions, monitoring needs, patient preferences, and local approvals.
There is no single laboratory turnaround time or specimen protocol that applies to every jurisdiction. The pathology or oncology office can provide the expected timing for its laboratory and explain whether testing is performed locally or sent to a reference service.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
Adjuvant therapy versus treatment for advanced disease
“Adjuvant” means treatment after surgery when no visible tumor remains. The objective is to lower the chance that microscopic residual cells will produce a future relapse. Evidence and recommendations for this setting should not be mixed with regimens used when GIST is unresectable, recurrent, or metastatic.
For advanced disease, the presence of a driver mutation can guide selection among TKIs and later lines of therapy. The D842V example shows why the distinction matters: avapritinib may be relevant when that mutation is driving advanced disease, but its use does not create a routine postoperative indication. The same genotype can therefore lead to “no adjuvant imatinib” after surgery and a genotype-directed TKI discussion if disease later becomes unresectable.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Monitoring and practical issues during an imatinib discussion
The prescribed dose and duration should appear explicitly in the treatment plan. For the standard adjuvant pathway, that means 400 mg once daily for three years; for KIT exon 9, the plan may specify 800 mg daily if the specialist team recommends it. Patients should ask how tablets are to be taken, what to do after a missed dose, and which prescription, over-the-counter, or herbal products could interact with treatment.
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Monitoring is individualized. The oncology team follows tolerability, laboratory results, other medicines, and any change in health that could alter the risk-benefit balance. A planned interruption or dose change should be made by the treating team rather than by stopping abruptly or reducing the dose independently. The exact monitoring schedule is determined by the clinician and local protocol.
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
Three examples of how the logic works
Example 1: high-risk, imatinib-sensitive tumor
A resected gastric GIST has a significant recurrence risk, clear margins, and an imatinib-sensitive KIT alteration. The mutation supports the drug choice, while the risk classification supplies the reason to use postoperative therapy. The team can discuss the three-year, 400 mg daily standard and whether the patient’s other health issues permit it.
Example 2: high-risk D842V tumor
A completely removed GIST has features associated with substantial relapse risk, but sequencing identifies PDGFRA exon 18 D842V. The high-risk pathology does not override the resistance result. Guidelines advise against adjuvant imatinib; follow-up and any future treatment are planned around the tumor’s biology and clinical status.
Example 3: KIT exon 9 with borderline tolerance concerns
A patient with a significant-risk KIT exon 9 GIST asks why the prescription is not automatically the usual dose. The answer is that exon 9 has lower sensitivity to standard-dose imatinib, so a specialist may consider 800 mg daily. Kidney or liver problems, interacting medicines, prior intolerance, and local authorization can still influence the final plan.
Recommended Free Tools
Questions to ask the sarcoma team
- Which exact mutation and exon did the report identify?
- Is the alteration considered imatinib-sensitive, less sensitive, or resistant?
- What recurrence-risk category results from the tumor size, site, mitotic rate, rupture status, and margins?
- Was the tumor completely resected, and is there any concern about microscopic residual disease?
- If imatinib is recommended, why this dose and why three years?
- If KIT exon 9 is present, has the team considered the 800 mg option, and is it approved locally?
- If the result is wild-type, has SDH-deficient, NF1-associated, or another subtype been considered?
- What monitoring, interaction checks, and follow-up schedule will apply?
- Which parts of the plan are based on adjuvant evidence and which would apply only if disease becomes advanced?
What the major guidelines establish—and what they do not
ESMO-EURACAN-GENTURIS (2021) sets the three-year, 400 mg daily standard for significant-risk, imatinib-sensitive resected GIST and identifies D842V as an exception to adjuvant treatment. NCCN (2022) describes activating KIT and PDGFRA mutations as the primary drivers in most GIST and discusses genotype-directed therapy in advanced disease. The National Cancer Institute explains the TKI mechanism and the poor expected benefit of imatinib for D842V tumors. SEOM-GEIS (2022) makes molecular testing mandatory when adjuvant therapy is indicated.
These are population-level recommendations, not an individualized prescription. The treating sarcoma team must reconcile the assay report with the complete pathology, surgical findings, medical history, drug interactions, patient preferences, and approvals in the patient’s country.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
